Methods CP or NP regimens were used. CP regimen involved CTX 0.8 g in 40 ml normal saline by iv injection and DDP 100 mg/m~(2)by abdominal infusion on the first day.

方法CP方案为环磷酰胺(CTX)0.8 g加入生理盐水40 m l内静推,第1天,顺铂(DDP)100 mg/m2腹腔内注入,第1天;

[Conclusion]Better but similar therapeutic efficacy has been obtained in patients with RMBC treated by TA and NP regimens. Although the median duration of survival in TA group seems rather longer than in NP group,there is no statistical significance yet.

Objective To evaluate the short-time effects and toxic side-effects of EP, GP, NP regimens for patients with advanced Non-small Cell Lung Cancer (NSCLC).

Objective: To compare the efficacy and toxicity in the treatment of non-small-cell lung cancer (NSCLC) with NP and MVP regimen Methods: Through every 21 to 28 days cycle, systemic administration of NP and MVP combination chemotherapeutic regimen, a total of 246 cases of advanced stage non-small-cell lung cancer were enrolled Among them, 159 cases were adenocarcinoma, 55 squamous cell carcinoma and 32 others Chemotherapy-naive patients account for 177 cases and 69 recurrent diseases...

Objective: To compare the efficacy and toxicity in the treatment of non-small-cell lung cancer (NSCLC) with NP and MVP regimen Methods: Through every 21 to 28 days cycle, systemic administration of NP and MVP combination chemotherapeutic regimen, a total of 246 cases of advanced stage non-small-cell lung cancer were enrolled Among them, 159 cases were adenocarcinoma, 55 squamous cell carcinoma and 32 others Chemotherapy-naive patients account for 177 cases and 69 recurrent diseases Results: The response rate were 35 7%(35/98) for NP regimen and 34 5%(51/148) for MVP regimen respectively There was no statistical significant difference ( P >0 05) between them Median time to progression were 5 months for NP and 4 months for MVP Median survival time were 11 months for NP and 8 months for MVP There was no significant difference ( P >0 05) for both of them between two groups The major toxicity was bone marrow suppression Grade Ⅲ～Ⅳleukopenia occurred in 50%of the NP group and 38 5%of the MVP group There was a significant difference ( P < 0 05) between two groups Grade Ⅲ～Ⅳthrombocytopenia was 4 1%in NP group and 7 4%in MVP group ( P >0 05) In grade Ⅲ～Ⅳ, nausea and vomiting were observed in 15 3%with NP and 18 2%with MVP ( P >0 05) and mainly occurred with grade Ⅲtoxicity in both groups Conclusion: Higher but similar response rates were seen in patients with NSCLC treated with NP and MVP regimens The median survival, although not significant was in favor of NP regimen Significant leukopenia occurred but was all tolerated well

Objective To evaluate effect of navelbine on non small cell lung cancer (NSCLC). Methods Forty eight cases of cytologically and pathologically confirmed advanced NSCLC were treated with combined chemotherapy including navelbine as the cardinal drug from May, 1995 to January, 1988. They were randomly divided into two groups. One group of 20 cases was treated with NP regimen (NVB+PDD); the other group of 28 cases was treated with NI regimen (NVB+IFO). All patients received no previous treatment....

Objective To evaluate effect of navelbine on non small cell lung cancer (NSCLC). Methods Forty eight cases of cytologically and pathologically confirmed advanced NSCLC were treated with combined chemotherapy including navelbine as the cardinal drug from May, 1995 to January, 1988. They were randomly divided into two groups. One group of 20 cases was treated with NP regimen (NVB+PDD); the other group of 28 cases was treated with NI regimen (NVB+IFO). All patients received no previous treatment. Results There was no complete response in patients treated with either regimen. Partial response was observed in 8 of 20 NP treated patients(40.0%) and in 12 of 28 NI treated patients (42.8%). There was no statistical difference in response rate between these 2 groups of NSCLC patients, However, in both groups of patients, the therapeutic effect was better in adenocarcinoma than in sequamous cell carcinoma patients. NP regimen seemed effective in the control of bone metastases and pains. Side effects were mainly myelo suppression and digestive tract reaction. Conclusion Combined chemotherapy including NVB is worthy of use in the treatment of advanced NSCLC especially for those with bone metastasis.

Objective:To evaluate the curative effects of NP(NVB+ PDD) regimen and MVP (MMC + VDS + PDD) regimen on advanced non - small cell lung cancer. Methods:63 cases of advanced non - small cell lung cancer who firstly received chemothera-py were randomly divided into two groups. NP regimen consisted of NVB 25~30mg/m2(dl?d5 iv drop), PDD 50mg(d2?d3 iv drop) . MVP regimen consisted of MMC 6mg/m2(d1 iv), VDS 3mg/m2(dl ?d8 iv drop), PDD 50mg(d2?d3 iv drop), every 3 weeks for at least two...

Objective:To evaluate the curative effects of NP(NVB+ PDD) regimen and MVP (MMC + VDS + PDD) regimen on advanced non - small cell lung cancer. Methods:63 cases of advanced non - small cell lung cancer who firstly received chemothera-py were randomly divided into two groups. NP regimen consisted of NVB 25~30mg/m2(dl?d5 iv drop), PDD 50mg(d2?d3 iv drop) . MVP regimen consisted of MMC 6mg/m2(d1 iv), VDS 3mg/m2(dl ?d8 iv drop), PDD 50mg(d2?d3 iv drop), every 3 weeks for at least two cycles. Results: 33 cases were treated with NP regimen, 30 cases with MVP regimen. The results showed that the re-sponse rates of NP regimen and MVP regimen were 51.5% (17/33) and 46.67(14/30) respectively. There was no statistical signifi-cant difference between them (P>0.05) . In NP group, there were 3 cases showing complete remission. The main toxicity were myelosuppressian. The NP regimen was more seroius than MVP regimen. The NP regimen mainly caused the third degree of myelo-suppression. There was statistical significant difference(P<0.05). Conclusion: It is concluded that both NP regimen and MVP regi-men may be used as first - line regimens for the treatment of advanced non - small cell lung cancer.

目的:对比NP方案和MVP方案治疗晚期NSCLC的疗效.方法:63例首次化疗的晚期NSCLC病人,依住院的先后顺序随机分为NP组和MVP组.NP方案:NVB25～30mg/m~2d1、d5iv,PDD 50mg d2、d3 iv drop.MVP方案:MMC6mg/m~2 d_1 iv,VDS 3mg/m~2 d1、d8 iv drop,PDD用法同NP方案.21天为一周期,满二个周期者进行疗效评估.结果:NP组有效率为51.5%(17/33),其中3例达到完全缓解;MVP组有效率为46.67%(14/30),两组疗效差异无显著意义(P>0.05).副作用均主要为骨髓抑制,NP组所致骨髓抑制多为Ⅲ度,两组间有显著差异(P<0.05).结论:NP方案和MVP方案可做为晚期NSCLC的一线化疗方案.